Oncolytic Virotherapy Market is predicted to reach USD 0.27 billion at a CAGR of 23.60% during the forecast period 2024-2032

Market Research Future (MRFR) has published on the “Global Oncolytic Virotherapy Market”.

The oncolytic virotherapy market is estimated to register a CAGR of 23.60% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global oncolytic virotherapy market - Lokon Pharma, Amgen, Transgene SA, Vyriad, Sorrento Therapeutics, Oncolys BioPharma, Targovax, CG Oncology Inc., TILT Biotherapeutics, VCNBiosciences, DNAtrix, and Replimune Group Inc.

Oncolytic Virotherapy Market Highlights

The global oncolytic virotherapy market is accounted to register a CAGR of 23.60% during the forecast period and is estimated to reach USD 0.27 billion by 2032.

The global cancer incidence rate is on the rise, which will drive the oncolytic virotherapy market. Since oncolytic virotherapy has potent anti-tumor capabilities and may precisely target tumors without damaging adjacent tissues, they are frequently utilized to treat a variety of malignancies, including glioblastoma, breast, lung, and prostate cancers. Accordingly, the therapy's broad use in treating a variety of melanomas, including lymphomas, leukemia, myeloma, and hematological malignancies, is supporting the oncolytic virotherapy market's expansion. Moreover, growing patient worries about the detrimental effects of several cancer treatments, like surgery, radiation, chemotherapy, and immunotherapy, are driving a significant portion of the oncolytic virotherapy market expansion.

Segment Analysis

The global oncolytic virotherapy market has been segmented into type and application.

On the basis of type, the market is segmented into HSV-based Oncolytic Viruses, Adenoviruses-based Oncolytic Viruses, and Others. The adenoviruses-based oncolytic viruses segment was attributed to holding the largest market share in 2023 due to its ability to target and eradicate cancer cells effectively. Adenovirus-based oncolytic viruses have several benefits, including comparatively low toxicity, strong tumor selectivity, and the capacity to elicit an immune response.

Based on application, the global oncolytic virotherapy market has been segmented into Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, and Others. The breast cancer segment was expected to hold the largest market share in 2023 due to the high incidence of breast cancer cases throughout the world and the notable developments in oncolytic virotherapy for the treatment of breast cancer. The benefits of immunotherapy for breast cancer have also been brought to the attention of patients and healthcare professionals, which has further stimulated market expansion.

Explore In-depth Market Details [Table of Content, List of Figures, List of Tables] of oncolytic virotherapy market Research Report

Regional Analysis

The global oncolytic virotherapy market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of the US and Canada. The Europe oncolytic virotherapy market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The oncolytic virotherapy market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World oncolytic virotherapy market comprises the Middle East, Africa, and Latin America.

The North American regional sector maintained the largest market share for oncolytic virotherapy because hematopoietic malignancies like leukemia and lymphoma are becoming more common. There are huge investments in drug advancements. The partial availability of reimbursement coverage is the primary factor propelling the increase in market value.

Moreover, the Europe market has been persistently growing over the forecast period. This region is expanding due to a number of factors, including a huge patient population, increased cancer prevalence, and expanding healthcare infrastructure. The oncolytic virotherapy market is expanding due in part to expenditures in research & development as well as encouraging government efforts.

Additionally, Asia Pacific is anticipated to experience the quickest growth over the forecast period because cancer is becoming common, and people are becoming more aware of the many cancer treatment options. Moreover, substantial investment in research and development to create cutting-edge cancer treatment methods is probably going to contribute to the growth of the oncolytic virotherapy market.

Furthermore, the rest of the world's oncolytic virotherapy market is divided into the Middle East, Africa, and Latin America. The need for advanced therapies and innovative treatments is growing, and more government campaigns to raise awareness of cancer's various causes and encourage early diagnosis are expected to fuel oncolytic virotherapy market expansion. The rest of world is expanding at a notable rate as a result of this.

Key Findings of the Study

• The global oncolytic virotherapy market is expected to reach USD 0.27 billion by 2032, at a CAGR of 23.60% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to the rising incidence of cancer and increased public awareness of the variety of cancer treatment alternatives.


• Based on application, the breast cancer segment was attributed to holding the largest market in 2023, with an approximate market share of 42%.


• Lokon Pharma, Amgen, Transgene SA, Vyriad, Sorrento Therapeutics, Oncolys BioPharma, Targovax, CG Oncology Inc., TILT Biotherapeutics, VCNBiosciences, DNAtrix, and Replimune Group Inc. are the key market players.